Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival
Background and Aims: Although most ovarian cancers express estrogen (ER), progesterone (PR), and androgen (AR) receptors, they are currently not applied in clinical decision making. We explored the prognostic impact of sex steroid hormone receptor protein and mRNA expression on survival in epithelia...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-10-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S193652331500073X |
id |
doaj-4c17d2cdcd7b4afba96f4e5b0d7d131f |
---|---|
record_format |
Article |
spelling |
doaj-4c17d2cdcd7b4afba96f4e5b0d7d131f2020-11-25T01:56:07ZengElsevierTranslational Oncology1936-52332015-10-0185424433Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer SurvivalJenny-Maria Jönsson0Nicolai Skovbjerg Arildsen1Susanne Malander2Anna Måsbäck3Linda Hartman4Mef Nilbert5Ingrid Hedenfalk6Division of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; Address all correspondence to: Jenny-Maria Jönsson, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University Cancer Center/Medicon Village, Building 404:B3, Scheelevägen 2, SE-223 81 Lund, Sweden.Division of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, SwedenDivision of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, SwedenDepartment of Surgical Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, SwedenDivision of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; Regional Cancer Center South Sweden, Lund, SwedenDivision of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; Clinical Research Centre, Hvidovre University Hospital, Copenhagen University, DenmarkDivision of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, SwedenBackground and Aims: Although most ovarian cancers express estrogen (ER), progesterone (PR), and androgen (AR) receptors, they are currently not applied in clinical decision making. We explored the prognostic impact of sex steroid hormone receptor protein and mRNA expression on survival in epithelial ovarian cancer. Methods: Immunohistochemical stainings for ERα, ERβ, PR, and AR were assessed in relation to survival in 118 serous and endometrioid ovarian cancers. Expression of the genes encoding the four receptors was studied in relation to prognosis in the molecular subtypes of ovarian cancer in an independent data set, hypothesizing that the expression levels and prognostic impact may differ between the subtypes. Results: Expression of PR or AR protein was associated with improved 5-year progression-free (P = .001 for both) and overall survival (P < .001 for both, log-rank test). ERα and ERβ did not provide prognostic information. Patients whose tumors coexpressed PR and AR had the most favorable prognosis, and this effect was retained in multivariable analyses. Analyses of the corresponding genes using an independent data set revealed differences among the molecular subtypes, but no clear relationship between high coexpression of PGR and AR and prognosis. Conclusions: A favorable outcome was seen for patients whose tumors coexpressed PR and AR. Gene expression data suggested variable effects in the different molecular subtypes. These findings demonstrate a prognostic role for PR and AR in ovarian cancer and support that tumors should be stratified based on molecular as well as histological subtypes in future studies investigating the role of endocrine treatment in ovarian cancer.http://www.sciencedirect.com/science/article/pii/S193652331500073X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jenny-Maria Jönsson Nicolai Skovbjerg Arildsen Susanne Malander Anna Måsbäck Linda Hartman Mef Nilbert Ingrid Hedenfalk |
spellingShingle |
Jenny-Maria Jönsson Nicolai Skovbjerg Arildsen Susanne Malander Anna Måsbäck Linda Hartman Mef Nilbert Ingrid Hedenfalk Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival Translational Oncology |
author_facet |
Jenny-Maria Jönsson Nicolai Skovbjerg Arildsen Susanne Malander Anna Måsbäck Linda Hartman Mef Nilbert Ingrid Hedenfalk |
author_sort |
Jenny-Maria Jönsson |
title |
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
title_short |
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
title_full |
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
title_fullStr |
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
title_full_unstemmed |
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
title_sort |
sex steroid hormone receptor expression affects ovarian cancer survival |
publisher |
Elsevier |
series |
Translational Oncology |
issn |
1936-5233 |
publishDate |
2015-10-01 |
description |
Background and Aims: Although most ovarian cancers express estrogen (ER), progesterone (PR), and androgen (AR) receptors, they are currently not applied in clinical decision making. We explored the prognostic impact of sex steroid hormone receptor protein and mRNA expression on survival in epithelial ovarian cancer. Methods: Immunohistochemical stainings for ERα, ERβ, PR, and AR were assessed in relation to survival in 118 serous and endometrioid ovarian cancers. Expression of the genes encoding the four receptors was studied in relation to prognosis in the molecular subtypes of ovarian cancer in an independent data set, hypothesizing that the expression levels and prognostic impact may differ between the subtypes. Results: Expression of PR or AR protein was associated with improved 5-year progression-free (P = .001 for both) and overall survival (P < .001 for both, log-rank test). ERα and ERβ did not provide prognostic information. Patients whose tumors coexpressed PR and AR had the most favorable prognosis, and this effect was retained in multivariable analyses. Analyses of the corresponding genes using an independent data set revealed differences among the molecular subtypes, but no clear relationship between high coexpression of PGR and AR and prognosis. Conclusions: A favorable outcome was seen for patients whose tumors coexpressed PR and AR. Gene expression data suggested variable effects in the different molecular subtypes. These findings demonstrate a prognostic role for PR and AR in ovarian cancer and support that tumors should be stratified based on molecular as well as histological subtypes in future studies investigating the role of endocrine treatment in ovarian cancer. |
url |
http://www.sciencedirect.com/science/article/pii/S193652331500073X |
work_keys_str_mv |
AT jennymariajonsson sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT nicolaiskovbjergarildsen sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT susannemalander sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT annamasback sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT lindahartman sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT mefnilbert sexsteroidhormonereceptorexpressionaffectsovariancancersurvival AT ingridhedenfalk sexsteroidhormonereceptorexpressionaffectsovariancancersurvival |
_version_ |
1724981465531285504 |